News | May 27, 2021
Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated
